Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron

Cancer Science

Volumn 106, Issue 7, 2015, Pages 891-895

  Komatsu, Yoshito ^a   Okita, Kenji ^b   Yuki, Satoshi ^a   Furuhata, Tomohisa ^b   Fukushima, Hiraku ^a   Masuko, Hiroyuki ^c   Kawamoto, Yasuyuki ^d   Isobe, Hiroshi ^e   Miyagishima, Takuto ^f   Sasaki, Kazuaki ^g   Nakamura, Michio ^h   Ohsaki, Yoshinobu ⁱ   Nakajima, Junta ^j   Tateyama, Miki ^k   Eto, Kazunori ^l   Minami, Shinya ^m   Yokoyama, Ryoji ⁿ   Iwanaga, Ichiro ^o   Shibuya, Hitoshi ^p   Kudo, Mineo ^q   Oba, Koji ^r   Takahashi, Yasuo ^s   more..

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c Sapporo Kosei General Hospital   (Japan)

^d Hakodate Municipal Hospital   (Japan)

^e KKR Sapporo Medical Center   (Japan)

^f KUSHIRO ROSAI HOSPITAL   (Japan)

^g Otaru Ekisaikai Hospital   (Japan)

^h SAPPORO CITY GENERAL HOSPITAL   (Japan)

ⁱ ASAHIKAWA MEDICAL COLLEGE   (Japan)

^j Obihiro Kousei General Hospital   (Japan)

^k Tomakomai Nisshou Hospital   (Japan)

^l Tomakomai City Hospital   (Japan)

^m Oji General Hospital   (Japan)

ⁿ Iwamizawa Municipal General Hospital   (Japan)

^o Japanese Red Cross Kitami Hospital   (Japan)

^p Muroran City General Hospital   (Japan)

^q SAPPORO HOKUYU HOSPITAL   (Japan)

^r UNIVERSITY OF TOKYO   (Japan)

^s HOKKAIDO CANCER CENTER   (Japan)

more..

Author keywords

Chemotherapy induced nausea and vomiting; Dexamethasone; Moderately emetogenic chemotherapy; Palonosetron; Phase III

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOPAMINE RECEPTOR BLOCKING AGENT; IRINOTECAN; NEUROLEPTIC AGENT; OXALIPLATIN; PALONOSETRON; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; ISOQUINOLINE DERIVATIVE; PLATINUM COMPLEX; QUINUCLIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HICCUP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODERATELY EMETOGENIC CHEMOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OPTIMAL DRUG DOSE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; NAUSEA; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEXAMETHASONE; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 84936985826     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12675     Document Type: Article

References (14)

1. Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 2007; 3: 1009-20.
2. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1: 331-40.
3. Morita S, Kobayashi K, Eguchi K et al. Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 2003; 33: 470-6.
4. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-8.
5. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(Suppl 5): v232-43.
6. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004; 64: 1125-32; discussion 1133-4.
7. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-24.
8. Aapro M, Fabi A, Nolè F et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010; 21: 1083-8.
9. Celio L, Frustaci S, Denaro A et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011; 19: 1217-25.
10. Gail M, Simon R. Tests for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361-72.
11. Segawa Y, Aogi K, Inoue K et al. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann Oncol 2009; 20: 1874-80.
12. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000; 18: 3409-22.
13. Rojas C, Li Y, Zhang J et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 2010; 335: 362-8.
14. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999; 4: 191-6.